Market news

aTyr Pharma reached FDA alignment on a Phase 3 study for efzofitimod to treat pulmonary sarcoidosis, beginning in Q4 2026.

aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod. Following this regulatory alignment, the company prepares to initiate study-related activities across the U.S. and Europe in the fourth quarter of 2026. Phase 3 Trial Design And Endpoints The upcoming Phase 3 clinical trial aims to assess both the overall safety and effectiveness of efzofitimod in individu

aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor TakeawaysaTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis.

Global Phase 3 study will evaluate efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint. Company expects to initiate study-related activities in the fourth quarter of 2026. SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, toda

Company anticipates response from FDA by mid-September 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis with restrictive lung disease.SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today provided an update on the expected timing

Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for planned Phase 3 study of efzofitimod in patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged